A Phase 2 interventional study of VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) in COVID-19, sponsored by Aerogen Pharma Limited. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Aerogen Pharma Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,860 studies in COVID-19 with a site in United States, this one is the 1,127th largest by enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 350 in phase 2, and was the 490th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,860 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 482 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 92 across the 1,322 interventional studies, 300 across the 521 observational. Of the 1,415 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,860 have an industry lead sponsor. The 10 most frequent:
Aerogen Pharma Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Aerogen Pharma Limited has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
84 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,860 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
This study will evaluate the potential therapeutic benefit of VentaProst in treating patients with COVID-19 at risk for respiratory and/ or cardiac/circulatory failure. This is a double-blind, placebo controlled study of VentaProst in 10 confirmed COVID-19 patients compared to 10- COVID-19 placebo patients to assess the efficacy and safety of VentaProst given over 10 days at varying doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Up to 10 days of inhaled epoprostenol delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Up to 10 days of inhaled 0.9% sodium chloride solution delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
Also known as: inhaled Flolan
Change in Respiratory Failure
Number of participants that were extubated
Time frame: 10 days post-randomization
Change in Cardiac/Circulatory Failure
Number of participants that required ECMO or left ventricular assist device (LVAD)
Time frame: 10 days post-randomization
| Milestone | Study Treatment | Placebo Control |
|---|---|---|
| Started | 6 | 5 |
| Completed | 5 | 1 |
| Not completed | 1 | 4 |
| Withdrew: Death | 1 | 4 |
Number of participants that were extubated
| Participants | Study Treatment | Placebo Control |
|---|---|---|
| Change in Respiratory Failure | 3 | 2 |
Number of participants that required ECMO or left ventricular assist device (LVAD)
| Participants | Study Treatment | Placebo Control |
|---|---|---|
| Change in Cardiac/Circulatory Failure | 0 | 0 |
Collected over Adverse event data were collected from randomization through 28 days post-randomization.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study Treatment | 1/6 (16.7%) | 1/6 (16.7%) | 0/6 (0%) |
| Placebo Control | 4/5 (80%) | 4/5 (80%) | 1/5 (20%) |
| Event | Study Treatment | Placebo Control |
|---|---|---|
| Worsening of Acute Hypoxic Respiratory FailureRespiratory, thoracic and mediastinal disorders | 1/6 | 3/5 |
| Worsening of ARDSRespiratory, thoracic and mediastinal disorders | 0/6 | 1/5 |
| Hypercapnic Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/6 | 1/5 |
| Event | Study Treatment | Placebo Control |
|---|---|---|
| HypotensionCardiac disorders | 0/6 | 1/5 |
| Age, Customized(Participants) | Study Treatment | Placebo Control | Total |
|---|---|---|---|
| <65 years | 3 | 2 | 5 |
| >65 years | 3 | 3 | 6 |
| Sex: Female, Male(Participants) | Study Treatment | Placebo Control | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 3 | 3 | 6 |
| Race and Ethnicity Not Collected(Participants) | Study Treatment | Placebo Control | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Jun 2021, 9 months.
Results were first posted in Jul 2025, 4 years 1 month after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 9 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoprostenol
Aerogen Pharma Limited